Explore GLP-1 receptor agonists with experts Judith Heij-Hadavi and Nicole Snow: molecular design, patient care, oral therapies, and analytical insights.
GLP-1 Therapies in Transition: Analytical and Clinical Insights for Experts
In the second episode of our GLP-1 Therapy Insights series, experts Judith Hey-Hadavi from Worldwide Clinical Trials and Nicole Snow from Olympia Pharmaceuticals discuss the evolution of GLP-1 receptor agonists from protein-based therapies to small-molecule options.
This episode examines the pharmacologic basis of GLP-1 adverse reactions, dose titration strategies, and patient-specific factors shaping therapy safety.
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
